Bicara Therapeutics Inc. Diluted Shares Outstanding (Weighted Average)
Bicara Therapeutics Inc. (BCAX) reported Diluted Shares Outstanding (Weighted Average) of 67.93 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-11
- Bicara Therapeutics Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 67.93M shares, a 24.55% increase year-over-year.
- Bicara Therapeutics Inc. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 60.72M shares, a 11.50% increase year-over-year.
- Bicara Therapeutics Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 218.54B shares, a 225.17% increase year-over-year.
- Bicara Therapeutics Inc. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 54.56M shares, a 400.53% increase year-over-year.
- Bicara Therapeutics Inc. weighted average number of shares outstanding, diluted for fiscal 2025 was 54.68B shares, a 225.35% increase from fiscal 2024.
- Bicara Therapeutics Inc. weighted average number of shares outstanding, diluted for fiscal 2024 was 16.81B shares, a 2796.96% increase from fiscal 2023.
- Bicara Therapeutics Inc. weighted average number of shares outstanding, diluted for fiscal 2023 was 580.11M shares.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | 67.93M shares 10-Q · filed 2026-08-11 | 64.36M shares 10-Q · filed 2026-08-11 | 72.89B shares derived: average of 3 quarters · filed 2026-08-11 | 54.68B shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 60.72M shares 10-Q · filed 2026-05-11 | 109.30B shares derived: average of 2 quarters · filed 2026-05-11 | 72.89B shares derived: average of 3 quarters · filed 2026-05-11 | 54.68B shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 218.54B shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 109.30B shares derived: average of 2 quarters · filed 2026-03-30 | 72.88B shares derived: average of 3 quarters · filed 2026-08-11 | 54.68B shares 10-K · filed 2026-03-30 |
| 2025-09-30 | 54.56M shares 10-Q · filed 2025-11-10 | 54.55M shares derived: average of 2 quarters · filed 2026-08-11 | 54.52M shares 10-Q · filed 2025-11-10 | 16.84B shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 54.54M shares 10-Q · filed 2026-08-11 | 54.50M shares 10-Q · filed 2026-08-11 | 22.44B shares derived: average of 3 quarters · filed 2026-08-11 | 16.83B shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 54.46M shares 10-Q · filed 2026-05-11 | 33.63B shares derived: average of 2 quarters · filed 2026-05-11 | 22.42B shares derived: average of 3 quarters · filed 2026-05-11 | 16.82B shares derived: average of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | 67.21B shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | 33.61B shares derived: average of 2 quarters · filed 2026-03-30 | 22.41B shares derived: average of 3 quarters · filed 2026-03-30 | 16.81B shares 10-K · filed 2026-03-30 |
| 2024-09-30 | 10.90M shares 10-Q · filed 2025-11-10 | 5.90M shares derived: average of 2 quarters · filed 2025-11-10 | 4.17M shares 10-Q · filed 2025-11-10 | 582.80M shares derived: average of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | 896.74K shares 10-Q · filed 2025-08-12 | 774.01K shares 10-Q · filed 2025-08-12 | 773.43M shares derived: average of 3 quarters · filed 2025-08-12 | 580.23M shares derived: average of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | 660.29K shares 10-Q · filed 2025-05-13 | 1.16B shares derived: average of 2 quarters · filed 2025-05-13 | 773.33M shares derived: average of 3 quarters · filed 2025-05-13 | |
| 2023-12-31 | 2.32B shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 1.16B shares derived: average of 2 quarters · filed 2025-03-27 | 580.11M shares 10-K · filed 2025-03-27 | |
| 2023-09-30 | 597.59K shares 10-Q · filed 2024-11-12 | 563.48K shares 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |